Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Literature DB >> 9559828

Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

G W Kaatz¹, S M Seo, J R Aeschlimann, H H Houlihan, R C Mercier, M J Rybak.

Abstract

The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1998 PMID： 9559828 PMCID： PMC105587 DOI： 10.1128/AAC.42.4.981

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors:
Journal: MMWR Morb Mortal Wkly Rep Date: 1997-08-22 Impact factor: 17.586

2. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

Authors: R S Schwalbe; A C McIntosh; S Qaiyumi; J A Johnson; R J Johnson; K M Furness; W J Holloway; L Steele-Moore
Journal: Antimicrob Agents Chemother Date: 1996-10 Impact factor: 5.191

3. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Authors: T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; M J Zweifel; S C Wilkie; M J Rodriguez; R C Thompson; R D Cooper
Journal: Antimicrob Agents Chemother Date: 1996-09 Impact factor: 5.191

4. Determination of vancomycin related substances by gradient high-performance liquid chromatography.

Authors: E L Inman
Journal: J Chromatogr Date: 1987-12-11

5. Automated fluorescence polarization immunoassay for monitoring vancomycin.

Authors: K S Schwenzer; C H Wang; J P Anhalt
Journal: Ther Drug Monit Date: 1983 Impact factor: 3.681

6. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

Authors: R N Jones; M S Barrett; M E Erwin
Journal: Antimicrob Agents Chemother Date: 1997-02 Impact factor: 5.191

7. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.

Authors: S Handwerger; B Raucher; D Altarac; J Monka; S Marchione; K V Singh; B E Murray; J Wolff; B Walters
Journal: Clin Infect Dis Date: 1993-06 Impact factor: 9.079

8. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.

Authors: G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal: Antimicrob Agents Chemother Date: 1990-02 Impact factor: 5.191

9. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.

Authors: W C Noble; Z Virani; R G Cree
Journal: FEMS Microbiol Lett Date: 1992-06-01 Impact factor: 2.742

10. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors: G W Kaatz; S L Barriere; D R Schaberg; R Fekety
Journal: Antimicrob Agents Chemother Date: 1987-04 Impact factor: 5.191

13 in total

1. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

Authors: J Gerber; A Smirnov; A Wellmer; J Ragheb; J Prange; E Schütz; K Wettich; S Kalich; R Nau
Journal: Antimicrob Agents Chemother Date: 2001-07 Impact factor: 5.191

2. Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.

Authors:
Journal: Curr Infect Dis Rep Date: 1999-06 Impact factor: 3.725

3. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Authors: A Saleh-Mghir; A Lefort; Y Petegnief; S Dautrey; J M Vallois; D Le Guludec; C Carbon; B Fantin
Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191

Review 4. Oritavancin for acute bacterial skin and skin structure infections.

Authors: Julia A Messina; Vance G Fowler; G Ralph Corey
Journal: Expert Opin Pharmacother Date: 2015-03-24 Impact factor: 3.889

5. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors: A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal: Antimicrob Agents Chemother Date: 2000-11 Impact factor: 5.191

Review 6. Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors: Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal: Drugs Date: 2004 Impact factor: 9.546

Review 7. New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors: J R Lentino; M Narita; V L Yu
Journal: Eur J Clin Microbiol Infect Dis Date: 2008-01 Impact factor: 3.267

8. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.

Authors: Carmen Cabellos; Antonio Fernàndez; Jose M Maiques; Fe Tubau; Carmen Ardanuy; Pedro F Viladrich; Josefina Liñares; Francesc Gudiol
Journal: Antimicrob Agents Chemother Date: 2003-06 Impact factor: 5.191

9. Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

Authors: Dario Lehoux; Valerie Ostiguy; Cordelia Cadieux; Mireille Malouin; Odette Belanger; Adel Rafai Far; Thomas R Parr
Journal: Antimicrob Agents Chemother Date: 2015-08-03 Impact factor: 5.191

Review 10. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors: Françoise Van Bambeke
Journal: Drugs Date: 2015-12 Impact factor: 9.546